Mikael Dolsten, MD, Ph.D.

Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at Pfizer, which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed medicines and vaccines. WRDM comprises all Pfizer research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation. The Vaccines R&D team leads scientific efforts from discovery through registration of novel vaccines. Mikael also has worldwide responsibility for Pfizer’s medical, safety and external R&D innovation, as well as science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Prior to joining Pfizer in 2009, Mikael was President of Wyeth Research, where he led scientists involved in all R&D/Medical activities across the US, Europe and Asia. Before that, Mikael served as Executive Vice President and Head of Worldwide Research for Boehringer Ingelheim from 2003-2008.